Hepatitis C genotype 4: The past, present, and future

Figure 1 Global hepatitis C virus genotype distribution. Johns Hopkins Hospital Division of Gastroenterology and Hepatology. Available from: URL: https://gi.jhsps.org/Upload/200710291122_15908_000.jpg.

Figure 2 Sustained virologic response to 48 wk of combination therapy in patients with hepatitis C virus genotype-4 using standard-dose pegylated-interferon and ribavirin (pegylated-interferon-α2a 180 μg or pegylated-interferon-α2b 1. 5 mg/kg and RBV 1-1.2 g/d). All studies were randomized control trials with intention-to-treat analysis: (P < 0.001) (P < 0.01) (P = not supplied) (P = 0.43)[128-131]. PEG-IFN: Pegylated-interferon; RBV: Ribavirin.

Figure 3 Results of hepatitis C virus genotype-4 treatments with pegylated-interferon and ribavirin: 24 wk vs 48 wk. (P = not reported) (P = 0.001) (P = 0.006) showing far less sustained virologic response rates with 24 wk of therapy[132-134].